Amino-terminal propeptide of C-type natriuretic peptide and linear growth in children

Effects of puberty, testosterone, and growth hormone

Robert C. Olney, Timothy C.R. Prickett, Timothy G. Yandle, Eric A. Espiner, Joan Han, Nelly Mauras

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Context: C-type natriuretic peptide (CNP), a paracrine factor of the growth plate, plays a key role in stimulating bone growth. The amino-terminal propeptide of CNP (NTproCNP) is produced in equimolar amounts with CNP and is measurable in plasma, providing a potential biomarker for growth plate activity and, hence, linear growth. Objective: We explored the effects of puberty, testosterone, and GH treatment on NTproCNP levels in normal and short-statured children. Design: This was a retrospective analysis of samples obtained during previous studies. Setting: The study was conducted at a pediatric clinical research center. Subjects: Children with short stature due to GH deficiency, idiopathic short stature (ISS), or constitutional delay of growth and maturation (CDGM) were studied (n = 37). A cohort of normal-statured adolescent boys was also studied (n = 23). Interventions: Children with GH deficiency and ISS were studied before and during testosterone and/or GH treatment. Boys with CDGM and healthy controls were studied once. Main Outcome Measures: The main outcomes were NTproCNP levels before and during growth-promoting therapy and during pubertal growth. Results: Children with short stature due to GH deficiency, ISS, or CDGM had comparable baseline levels of NTproCNP, and levels increased markedly in response to GH or testosterone treatment. In boys with CDGM, levels were comparable with height-matched controls but were less than those from age-matched controls. In healthy boys, NTproCNP appears to peak with the pubertal growth spurt. Conclusions: NTproCNP levels increase during growth-promoting therapy and are increased during puberty in boys. This novel biomarker of growth may have clinical utility in the evaluation of children with short stature and for monitoring growth-promoting therapy.

Original languageEnglish (US)
Pages (from-to)4294-4298
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume92
Issue number11
DOIs
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

C-Type Natriuretic Peptide
Puberty
Growth Hormone
Testosterone
Growth
Growth Plate
Biomarkers
Therapeutics
Bone Development
Pediatrics

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Amino-terminal propeptide of C-type natriuretic peptide and linear growth in children : Effects of puberty, testosterone, and growth hormone. / Olney, Robert C.; Prickett, Timothy C.R.; Yandle, Timothy G.; Espiner, Eric A.; Han, Joan; Mauras, Nelly.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 92, No. 11, 01.01.2007, p. 4294-4298.

Research output: Contribution to journalArticle

Olney, Robert C. ; Prickett, Timothy C.R. ; Yandle, Timothy G. ; Espiner, Eric A. ; Han, Joan ; Mauras, Nelly. / Amino-terminal propeptide of C-type natriuretic peptide and linear growth in children : Effects of puberty, testosterone, and growth hormone. In: Journal of Clinical Endocrinology and Metabolism. 2007 ; Vol. 92, No. 11. pp. 4294-4298.
@article{c473a9e7bc434546a7c4228a3b32f08a,
title = "Amino-terminal propeptide of C-type natriuretic peptide and linear growth in children: Effects of puberty, testosterone, and growth hormone",
abstract = "Context: C-type natriuretic peptide (CNP), a paracrine factor of the growth plate, plays a key role in stimulating bone growth. The amino-terminal propeptide of CNP (NTproCNP) is produced in equimolar amounts with CNP and is measurable in plasma, providing a potential biomarker for growth plate activity and, hence, linear growth. Objective: We explored the effects of puberty, testosterone, and GH treatment on NTproCNP levels in normal and short-statured children. Design: This was a retrospective analysis of samples obtained during previous studies. Setting: The study was conducted at a pediatric clinical research center. Subjects: Children with short stature due to GH deficiency, idiopathic short stature (ISS), or constitutional delay of growth and maturation (CDGM) were studied (n = 37). A cohort of normal-statured adolescent boys was also studied (n = 23). Interventions: Children with GH deficiency and ISS were studied before and during testosterone and/or GH treatment. Boys with CDGM and healthy controls were studied once. Main Outcome Measures: The main outcomes were NTproCNP levels before and during growth-promoting therapy and during pubertal growth. Results: Children with short stature due to GH deficiency, ISS, or CDGM had comparable baseline levels of NTproCNP, and levels increased markedly in response to GH or testosterone treatment. In boys with CDGM, levels were comparable with height-matched controls but were less than those from age-matched controls. In healthy boys, NTproCNP appears to peak with the pubertal growth spurt. Conclusions: NTproCNP levels increase during growth-promoting therapy and are increased during puberty in boys. This novel biomarker of growth may have clinical utility in the evaluation of children with short stature and for monitoring growth-promoting therapy.",
author = "Olney, {Robert C.} and Prickett, {Timothy C.R.} and Yandle, {Timothy G.} and Espiner, {Eric A.} and Joan Han and Nelly Mauras",
year = "2007",
month = "1",
day = "1",
doi = "10.1210/jc.2007-0567",
language = "English (US)",
volume = "92",
pages = "4294--4298",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Amino-terminal propeptide of C-type natriuretic peptide and linear growth in children

T2 - Effects of puberty, testosterone, and growth hormone

AU - Olney, Robert C.

AU - Prickett, Timothy C.R.

AU - Yandle, Timothy G.

AU - Espiner, Eric A.

AU - Han, Joan

AU - Mauras, Nelly

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Context: C-type natriuretic peptide (CNP), a paracrine factor of the growth plate, plays a key role in stimulating bone growth. The amino-terminal propeptide of CNP (NTproCNP) is produced in equimolar amounts with CNP and is measurable in plasma, providing a potential biomarker for growth plate activity and, hence, linear growth. Objective: We explored the effects of puberty, testosterone, and GH treatment on NTproCNP levels in normal and short-statured children. Design: This was a retrospective analysis of samples obtained during previous studies. Setting: The study was conducted at a pediatric clinical research center. Subjects: Children with short stature due to GH deficiency, idiopathic short stature (ISS), or constitutional delay of growth and maturation (CDGM) were studied (n = 37). A cohort of normal-statured adolescent boys was also studied (n = 23). Interventions: Children with GH deficiency and ISS were studied before and during testosterone and/or GH treatment. Boys with CDGM and healthy controls were studied once. Main Outcome Measures: The main outcomes were NTproCNP levels before and during growth-promoting therapy and during pubertal growth. Results: Children with short stature due to GH deficiency, ISS, or CDGM had comparable baseline levels of NTproCNP, and levels increased markedly in response to GH or testosterone treatment. In boys with CDGM, levels were comparable with height-matched controls but were less than those from age-matched controls. In healthy boys, NTproCNP appears to peak with the pubertal growth spurt. Conclusions: NTproCNP levels increase during growth-promoting therapy and are increased during puberty in boys. This novel biomarker of growth may have clinical utility in the evaluation of children with short stature and for monitoring growth-promoting therapy.

AB - Context: C-type natriuretic peptide (CNP), a paracrine factor of the growth plate, plays a key role in stimulating bone growth. The amino-terminal propeptide of CNP (NTproCNP) is produced in equimolar amounts with CNP and is measurable in plasma, providing a potential biomarker for growth plate activity and, hence, linear growth. Objective: We explored the effects of puberty, testosterone, and GH treatment on NTproCNP levels in normal and short-statured children. Design: This was a retrospective analysis of samples obtained during previous studies. Setting: The study was conducted at a pediatric clinical research center. Subjects: Children with short stature due to GH deficiency, idiopathic short stature (ISS), or constitutional delay of growth and maturation (CDGM) were studied (n = 37). A cohort of normal-statured adolescent boys was also studied (n = 23). Interventions: Children with GH deficiency and ISS were studied before and during testosterone and/or GH treatment. Boys with CDGM and healthy controls were studied once. Main Outcome Measures: The main outcomes were NTproCNP levels before and during growth-promoting therapy and during pubertal growth. Results: Children with short stature due to GH deficiency, ISS, or CDGM had comparable baseline levels of NTproCNP, and levels increased markedly in response to GH or testosterone treatment. In boys with CDGM, levels were comparable with height-matched controls but were less than those from age-matched controls. In healthy boys, NTproCNP appears to peak with the pubertal growth spurt. Conclusions: NTproCNP levels increase during growth-promoting therapy and are increased during puberty in boys. This novel biomarker of growth may have clinical utility in the evaluation of children with short stature and for monitoring growth-promoting therapy.

UR - http://www.scopus.com/inward/record.url?scp=35948964786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948964786&partnerID=8YFLogxK

U2 - 10.1210/jc.2007-0567

DO - 10.1210/jc.2007-0567

M3 - Article

VL - 92

SP - 4294

EP - 4298

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -